Podium to Practice: Chicago 2026 – LUNG: WU-KONG28

Podium to Practice: Chicago 2026 – LUNG: WU-KONG28

Podium to Practice: Chicago 2026

Studies / Trials Discussed

LBA8500 – Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).

Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Paul Wheatley-Price

Dr. Rosalyn Juergens

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

LBA8500 – Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
Tagged